Back to search results

Study of Orellanine for Metastatic Kidney Cancer

This study is testing a drug called Orellanine for people with advanced clear-cell or papillary renal cell carcinoma (a type of kidney cancer) that has spread to other parts of the body. You may be able to join if you have end-stage kidney disease and are receiving regular hemodialysis (a treatment that filters your blood). The main goals are to see how safe Orellanine is and if it causes any side effects, like changes in blood pressure or pulse. The study is currently in Part B, which is looking at different ways to give the drug and how long it stays in your system. Up to 75 people will participate in total.

Study design
This is an open-label (meaning you and your doctors will know what treatment you are receiving) Phase I/II study, which means it's looking at safety and early signs of effectiveness. It is not controlled, and up to 75 patients will be included.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety, including adverse events and changes in blood pressure and pulse, will be measured through study completion, which is approximately 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05287945

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

Recruiting
PHASE1Ages 18+InterventionalTreatment
Oncorena AB
~75 participants
Updated 2026-09-09 on ClinicalTrials.gov
What's tested:Orellanine

At a glance

Recruiting sites
9 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adverse events and laboratory abnormalities as graded by NCI CTCAE v5.0.
Measured over Through study completion, approximately 1 year
+6 more outcomes measured

Conditions

Carcinoma, Renal Cell

Explore related trials

Clear Cell Renal Cell CarcinomaPapillary Renal Cell Carcinoma

NCT05287945

Where you'd take part

This study runs at 9 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Clinica Mi Nova Alianca

    Lleida, Spainstudy coordinator listed

    Recruiting

  • Institut de Cancerologie Gustave-Roussy

    Villejuif, Francestudy coordinator listed

    Recruiting

  • Karolinska University Hospital

    Stockholm, Swedenstudy coordinator listed

    Recruiting

  • Stanford

    Palo Alto, Californiastudy coordinator listed

    Recruiting

  • START Lisbon - Hospital de Santa Maria Av

    Lisbon, Portugalstudy coordinator listed

    Recruiting

  • University of California Irvine

    Orange, Californiastudy coordinator listed

    Recruiting

  • University of California San Francisco

    San Francisco, Californiastudy coordinator listed

    Recruiting

  • University of Texas - MD Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Hanjing Xie, Ph.D.
[email protected]
+46737031615
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Adverse events and laboratory abnormalities as graded by NCI CTCAE v5.0.Through study completion, approximately 1 year
  • Changes in arterial blood pressure measurementsThrough study completion, approximately 1 year
  • Changes in pulse rate measurementsThrough study completion, approximately 1 year
  • Changes in respiratory rate measurementsThrough study completion, approximately 1 year
  • Changes in temperature measurementsThrough study completion, approximately 1 year
  • Changes in physical examination findingsThrough study completion, approximately 1 year
  • Maximum tolerable dose of orellanineThrough study completion, approximately 1 year